Choline-PET in prostate cancer management: The point of view of the radiation oncologist

Critical Reviews in Oncology/Hematology

Volumn 91, Issue 3, 2014, Pages 234-247

  De Bari, Berardino ^a   Alongi, Filippo ^b   Lestrade, Laëtitia ^c   Giammarile, Francesco ^d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Biochemical relapse; Choline PET; Prostate cancer; Staging; Treatment planning

Indexed keywords

CHOLINE C 11; FLUOROCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; TRACER; UNCLASSIFIED DRUG; CHOLINE; TUMOR MARKER;

ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; DIAGNOSTIC ACCURACY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; RADIATION ONCOLOGIST; RECURRENCE FREE SURVIVAL; REVIEW; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; TUMOR VOLUME; BONE NEOPLASMS; DIAGNOSTIC USE; GAMMA RADIATION; MALE; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; SECONDARY; THERAPEUTIC USE;

BONE NEOPLASMS; CHOLINE; GAMMA RAYS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904644824     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.04.002     Document Type: Review

References (88)

1. 11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients?. Acta Oncol 2014 Jan 17, [Epub ahead of print].
2. Chiti A., Kirienko M., Grégoire V. Clinical use of PET-CT data for radiotherapy planning: what are we looking for?. Radiother Oncol 2010, 96(September (3)):277-279.
3. Hara T., Kosaka N., Kishi H. PET imaging of prostate cancer using carbon-11-Choline. J Nucl Med 1998, 39:990-995.
4. Alongi F., De Bari B., Franco P., et al. The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiol Med 2013, 118(4):660-678.
5. De Bari B., Alongi F., Franco P., et al. The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part II) - a survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiol Med 2013 Oct, 118(7):1220-1239.
6. DeGrado T.R., Coleman R.E., Wang S., et al. Synthesis and evaluation of 18F labeled Choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 2001, 61:110-117.
7. Bentzen S.M. Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology. Cancer Treat Res 2008, 139:41-62.
8. Husarik D.B., Miralbell R., Dubs M., et al. Evaluation of [(18)F]-Choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:253-263.
9. Farsad M., Schiavina R., Castelluci P., et al. Detection and localization of prostate cancer: correlation of (11)C-Choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005, 46:1642-1649.
10. 11C-Choline PET and MRI imaging combined with proton MRI spectroscopy. Eur J Nucl Med Mol Imaging 2005, 32:742-748.
11. 11C-Choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006, 176:954-960.
12. 11C-choline PET/CT. J Nucl Med 2006, 47:1249-1254.
13. 11C-Choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007, 34:45-53.
14. 11C-Choline PET/CT. Radiology 2007, 244:797-806.
15. Giovacchini G., Picchio M., Coradeschi E., et al. [(11)C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumor stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008, 35:1065-1073.
16. 11C-Choline PET, 18F-fluorodeoxyglucose PET and MRI imaging. J Magn Reson Imaging 2010, 31:1151-1156.
17. 11C-Choline PET/CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?. Int J Radiat Oncol Biol Phys 2012, 83:1486-1492.
18. Kwee S.A., Coel M.N., Lim J., Ko J.P. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005, 173:252-255.
19. Kwee S.A., Thibault G.P., Stack R.S., Coel M.N., Furusato B., Sesterhenn I.A. Use of step-section histopathology to evaluate 18Ffluorocholine PET sextant localization of prostate cancer. Mol Imaging 2008, 7:12-20.
20. Igerc I., Kohlfurst S., Gallowitsch H.J., et al. The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localization of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:976-983.
21. 11C-Choline PET/CT for imaging prostate cancer: a pictorial guide. AJR 2011, 196:1390-1398.
22. 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009, 50:1585-1593.
23. 11C-Choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 2011, 17:3751-3759.
24. Beheshti M., Imamovic L., Broinger G., et al. 18F Choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010, 254:925-933.
25. 11C-Choline PET. J Nucl Med 2003 Mar, 44(3):331-335.
26. 11C-Choline positron emission tomography/computed tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008, 54:392-401.
27. 11C-Choline positron emission tomography/computed tomography and diffusion weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011, 60:125-130.
28. Poulsen M.H., Bouchelouche K., Hoilund-Carlsen P.F., et al. [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int 2012, 110:1666-1671.
29. Häcker A., Jeschke S., Leeb K., et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006 Nov, 176(5):2014-2018. [discussion 2018-2019].
30. 11C]Choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with Choline kinase expression. Clin Cancer Res 2011, 17:7673-7683.
31. Beheshti M., Vali R., Waldenberger P., et al. The use of F-18 Choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2009, 11:446-454.
32. Kjölhede H., Ahlgren G., Almquist H., Almquist H., et al. Combined 18 F-fluorocholine and 18 F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012, 110:1501-1506.
33. Langsteger W., Balogova S., Huchet V., et al. Fluorocholine (18F) and sodiumfluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 2011, 55:448-457.
34. 11C-Choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 2013, 34(October (10)):935-945.
35. Even-Sapir E., Metser U., Mishani E., Lievshitz G., Lerman H., Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006, 47(February (2)):287-297.
36. Wiechselbaum R.R., Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011, 8:378-382.
37. De Bari B., Guillet M., Mornex F. Stereotactic body radiation therapy (SBRT) in the treatment of liver metastases: state of the art. Cancer Radiother 2011, 15(February (1)):72-76.
38. Alongi F., De Bari B., Campostrini F., et al. Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review. Crit Rev Oncol Hematol 2013, 88(December (3)):550-563.
39. De Bari B., Alongi F., Buglione M., et al. Salvage therapy of small volume, limited extended prostate cancer nodal failures: a review of the literature. Crit Rev Oncol Hematol 2013, 10.1016/j.critrevonc.2013.11.003.
40. Salonen A.J., Taari K., Ala-Opas M., Viitanen J., Lundstedt S., Tammela T.L. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised Finn Prostate Study VII: quality of life and adverse effects. Eur Urol 2013, 63(January (1)):111-120.
41. Evangelista L., Zattoni F., Guttilla A., et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 2013, 38(May (5)):305-314.
42. Marzola M.C., Chondrogiannis S., Ferretti A., et al. Role of 18F-Choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA, velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med 2013, 38(January (1)):e26-e32.
43. Chondrogiannis S., Marzola M.C., Ferretti A., et al. Role of 18F-Choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging 2013, 40(September (9)):1356-1364.
44. Giovacchini G., Picchio M., Coradeschi E., et al. Predictive factors of [(11)C]Choline in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010, 37:301-319.
45. 11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35(January (1)):18-23.
46. 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1ng/mL) after radical prostatectomy. BJU Int 2007, 99(June (6)):1415-1420.
47. 11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003, 44(July (1)):32-38.
48. Rischke H.C., Knippen S., Kirste S., Grosu A.L. Treatment of recurrent prostate cancer following radical prostatectomy: the radiation-oncologists point of view. Q J Nucl Med Mol Imaging 2012, 56(October (5)):409-420.
49. King C.R., Kapp D.S. Radiotherapy after prostatectomy: is the evidence for dose escalation out there?. Int J Radiat Oncol Biol Phys 2008, 71:346-350.
50. Ost P., Cozzarini C., Bossi A., De Meerleer G. Salvage radiotherapy: a plea for dose-escalation with intensity-modulated radiotherapy. Eur J Cancer 2012, 48(June (9)):1415-1416.
51. Barentsz J.O., Richenberg J., Clements R., et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22:746-757.
52. De Bari B., Fiorentino A., Greto D., et al. Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the young radiation oncologist meeting. Tumori 2013, 99:637-649.
53. Panebianco V., Sciarra A., Lisi D., et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]Choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 2012, 81(April (4)):700-708.
54. 11C-Choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007, 52(August (2)):423-429.
55. 11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 2008, 81:191-197.
56. 11C]Choline positron emission tomography/computed tomography. Eur Urol 2011, 60(November (5)):935-943.
57. 11C]Choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int 2010, 84:418-423.
58. 11C-Choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008, 102:446-451.
59. 11C]Choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol 2013, [pii: S1078-1439(13)00171-3]. 10.1016/j.urolonc.2013.03.006.
60. 11C Choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med 2012, 37(April (4)):325-331.
61. 11C-Choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 2011, 38(November (11)):1985-1989.
62. 11C]Choline PET/CT. Clin Nucl Med 2010, 35:701-703.
63. 18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006, 33:977-984.
64. Emonds K.M., Swinnen J.V., van Weerden W.M., et al. Do androgens control the uptake of (18)F-FDG, (11)C-Choline and (11)C-acetate in human prostate cancer cell lines?. Eur J Nucl Med Mol Imaging 2011, 10.1007/s00259-011-1861-6.
65. Castellucci P., Fuccio C., Rubello D., et al. Is there a role for (11)C-Choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5ng/ml?. Eur J Nucl Med Mol Imaging 2011, 38:55-63.
66. Roach M., Faillace-Akazawa P., Malfatti C., Holland J., Hricak H. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996, 35(July (5)):1011-1018.
67. Villeirs G.M., Van Vaerenbergh K., Vakaet L., et al. Interobserver delineation variation using CT versus combined CT+MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol 2005, 181(July (7)):424-430.
68. van Baardwijk A., Baumert B.G., Bosmans G., et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 2006, 32:245-260.
69. Ippolito E., Mantini G., Morganti A.G., et al. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity. Am J Clin Oncol 2012, 35(April (2)):158-162.
70. Fonteyne V., Villeirs G., Speleers B., et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008, 72(3):799-807.
71. Niyazi M., Bartenstein P., Belka C., Ganswindt U. Choline PET based dose-painting in prostate cancer - modelling of dose effects. Radiat Oncol 2010, 5:23.
72. Chang J.H., Joon D.L., Lee S.T., Lee S.T., et al. Histopathological correlation of (11)C-Choline PET scans for target volume definition in radical prostate radiotherapy. Radiother Oncol 2011, 99(May (2)):187-192.
73. Seppala J., Seppanen M., Arponen E., et al. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol 2009, 93:234-240.
74. 18F-Choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 2010, 186(November (11)):600-606.
75. Pinkawa M., Piroth M.D., Holy R., et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-Choline PET-CT detected simultaneous integrated boost. Radiat Oncol 2012, 7(January):14.
76. 11C-Choline PET/CT on the treatment planning for savage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol 2011, 99:193-200.
77. 11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma. Q J Nucl Med Mol Imaging 2012, 56(October (5)):430-439.
78. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25(15):2035-2041.
79. Jereczek-Fossa B.A., Beltramo G., Fariselli L., et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastastic prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:889-897.
80. Scorsetti M., Bignardi M., Alongi F., et al. Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: feasibility and clinical preliminary results. Acta Oncol 2011, 50:528-538.
81. Casamassima F., Masi L., Menichelli C., et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with Choline PET scan in prostate cancer patients. Tumori 2011, 97(January-February (1)):49-55.
82. Fortuin A.S., Deserno W.M., Meijer H.J., et al. Value of PET/CT and MRI lymphography in treatment of prostate cancer patients with lymph node metastases. Int J Radiat Oncol Biol Phys 2012, 84(November (3)):712-718.
83. 18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 2011, 6:44.
84. 11C-Choline PET/CT image-guided radiotherapeutic treatment of lymph nodal recurrence in prostate cancer patients. Eur J Nucl Med Mol Imaging 2008, 35:288.
85. Schick U., Jorcano S., Nouet P., et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 2013, 52(November (8)):1622-1628.
86. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol 2009, 93:220-225.
87. Thorwarth D., Leibfarth S., Mönnich D. Potential role of PET/MRI in radiotherapy treatment planning. Clin Transl Imaging 2013, 1(1):45-51.
88. Afshar-Oromieh A., Haberkorn U., Schlemmer H.P., et al. Comparison of PET/CT and PET/MRI hybrid systems using 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2013, [Epub ahead of print].